Molecular biology and hepatocellular carcinoma: Current status and future prospects;Biologie moléculaire et carcinome hépatocellulaire: Données actuelles et développements futurs

Annales de Biologie Clinique

Volumn 62, Issue 6, 2004, Pages 649-656

  Saffroy, R ^a   Pham, P ^a   Lemoine, A ^a   Debuire, B ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Genetic alteration; Hepatocellular carcinoma; Molecular biology

Indexed keywords

DNA; TUMOR MARKER;

GENETIC MARKER; GENETICS; GENOME; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MOLECULAR BIOLOGY; REVIEW;

CARCINOMA, HEPATOCELLULAR; DNA, NEOPLASM; GENETIC MARKERS; GENOME, HUMAN; HUMANS; LIVER NEOPLASMS; MOLECULAR BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

HEPATITIS C VIRUS;

EID: 9644259191     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999 ; 49 : 33-64.
2. Saffroy R, Pham P, Chiappini F, et al. The MTHFR 677C > T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis 2004 ; 25 : 1443-8.
3. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002 ; 31 : 339-46.
4. Lin CH, Hsieh SY, Sheen IS, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001 ; 61 : 4238-43.
5. Saffroy R, Chiappini F, Debuire B, Lemoine A. Emerging concepts in the analysis of mitochondrial genome instability. Curr Genomics 2004 ; 5 : 309-25.
6. Bourdon JC, D'Errico A, Paterlini P, Grigioni W, May E, Debuire B. p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology 1995 ; 108 : 1176-82.
7. Saffroy R, Lelong JC, Azoulay D, et al. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 1999 ; 79 : 604-10.
8. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002 ; 8 : 385-92.
9. Soussi T. p53 antibodies in the sera of patients with various types of cancer : a review. Cancer Res 2000 ; 60 : 1777-88.
10. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001 ; 120: 1763-73.
11. Florentino M, Altimari A, Ravaioli M, et al. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin Cancer Res 2004 ; 10: 1789-95.
12. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002 ; 21 : 4863-71.
13. Jin M, Piao Z, Kim NG, et al. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 2000 ; 89 : 60-8.
14. Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2002 ; 8 : 638-43.
15. Salvucci M, Lemoine A, Saffroy R, et al. Microsatellite instability in European hepatocellular carcinoma. Oncogene 1999 ; 18 : 181-7.
16. Gross-Goupil M, Riou P, Emile JF, et al. Analysis of chromosomal instability in pulmonary or liver metastases and matched primary hepatocellular carcinoma after orthotopic liver transplantation. Int J Cancer 2003 ; 104 : 745-51.
17. Qin LX, Tang ZY, Sham JS, et al. The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res 1999 ; 59 : 5662-5.
18. Kuroki T, Fujiwara Y, Tsuchiya E, et al. Accumulation of genetic changes during development and progression of hepatocellular carcinoma : loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer 1995 ; 13 : 163-7.
19. Terracciano L, Tornillo L. Cytogenetic alterations in liver cell tumors as detected by comparative genomic hybridization. Pathologica 2003 ; 95 : 71-82.
20. Itano O, Ueda M, Kikuchi K, et al. A new predictive factor for hepatocellular carcinoma based on two-dimensional electrophoresis of genomic DNA. Oncogene 2000 ; 19 : 1676-83.
21. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Microsatellite instability associated with hepatocarcinogenesis. J Hepatol 1999 ; 31: 529-36.
22. Salvucci M, Lemoine A, Azoulay D, et al. Frequent microsatellite instability in post hepatitis B viral cirrhosis. Oncogene 1996 ; 13 : 2681-5.
23. Chiappini F, Gross-Goupil M, Saffroy R, et al. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. Carcinogenesis 2004 ; 25 : 541-7.
24. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003 ; 361 : 923-9.
25. Paradis V, Bleche I, Dargere D, et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003 ; 163 : 733-41.
26. Chang YC, Ho CL, Chen HH, et al. Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum. Br J Cancer 2002 ; 87 : 1449-53.
27. Niu Q, Tang ZY, Qin LX, Ma ZC, Zhang LH. Loss of heterozygosity at D14S62 and D14S51 detected by a simple and non-radioactive method in plasma DNA is a potential marker of metastasis and recurrence after curative hepatic resection in hepatocellular carcinoma. Hepatogastroenterology 2003 ; 50 : 1579-82.
28. Wong IH, Zhang J, Lai PB, Lau WY, Lo YM. Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin Cancer Res 2003 ; 9: 1047-52.
29. Lemoine A, Le Bricon T, Salvucci M, et al. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery. Ann Surg 1997 ; 226 : 43-50.
30. Gross-Goupil M, Saffroy R, Azoulay D, et al. Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Ann Surg 2003 ; 238 : 241-8.